Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ProgynyPGNY +1.25%94 Days Payable is 52.40 as of Mar. 2026, which is 19% above its 10-year median of 44.04. GuruFocus rates PGNY with a GF Score™ of 94/100 and a GF Value™ of $28.56 (Modestly Overvalued). The stock has 6 warning signs investors should review. Among 13 Healthcare Plans companies, Progyny ranks better than 61.54% on this metric.
Progyny's average Accounts Payable for the
three
months ended in Mar. 2026 was $141 Mil. Progyny's Cost of Goods Sold for the
three
months ended in Mar. 2026 was $245 Mil.
Hence, Progyny's Days Payable for the
three
months ended in Mar. 2026 was 52.40.
The historical rank and industry rank for Progyny's Days Payable or its related term are showing as below:
PGNY'
s Days Payable Range Over the Past 10 Years
Min: 34.65 Med: 44.04 Max: 51.42
Current: 51.42
During the past 9 years, Progyny's highest Days Payable was 51.42. The lowest was 34.65. And the median was 44.04.
PGNY's Days Payable is ranked better than 61.54% of 13
companies
in the Healthcare Plans industry
Industry Median: 38.89
vs PGNY: 51.42
Progyny's Days Payable
increased
from Mar. 2025 (44.26) to Mar. 2026 (52.40).
It may suggest that Progynydelayed paying its suppliers.
Progyny Days Payable Related Terms
Progyny Days Payable Historical Data
* Premium members only.
The historical data trend for Progyny's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Healthcare Plans subindustry, Progyny's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Progyny Days Payable vs Healthcare Plans Industry
For the Healthcare Plans industry and Healthcare sector, Progyny's Days Payable distribution charts can be found below:
* The bar in red indicates where Progyny's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Progyny's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Progyny (PGNY) has a Days Payable of 52.40 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Progyny and its competitors. This is 19% above median its historical median of 44.04. Over the past decade, Progyny's Days Payable has ranged from 34.65 to 51.42. According to the industry distribution chart, Progyny ranks #5 out of 13 companies in the Healthcare Plans industry, placing it in the top 38.5%.
Is Progyny's Days Payable too high?
Progyny's current Days Payable of 52.40 is 19% above median its 10-year median of 44.04. Over the past 10 years, this metric has ranged from a low of 34.65 to a high of 51.42. The Healthcare Plans industry median Days Payable is 38.89. Progyny's value of 52.40 is 34.7% above this industry median. Based on the distribution chart, Progyny ranks #5 out of 13 companies in the Healthcare Plans industry, which is above the industry midpoint. Overall, Progyny has a GF Score™ of 94/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Progyny's Days Payable compare to CLOV and ALHC?
According to the Healthcare Plans industry distribution chart, Progyny ranks #5 out of 13 companies for Days Payable. This puts Progyny in the upper half of its industry. The industry median Days Payable is 38.89. Progyny's value of 52.40 is 34.7% above this benchmark. Historically, Progyny's own Days Payable has ranged from 34.65 to 51.42 over the past decade. While the company's 10-year median is 44.04 vs. the industry median of 38.89, Progyny has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Healthcare Plans company?
The median Days Payable among Healthcare Plans companies is 38.89, based on 13 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Progyny's current Days Payable of 52.40 is 34.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Progyny and its competitors. For the Healthcare Plans industry, the median Days Payable is 38.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Progyny's current Days Payable is 52.40, which is 19% above median its own 10-year median of 44.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Progyny stock overvalued right now?
Based on GuruFocus' analysis, Progyny (PGNY) is currently considered Modestly Overvalued. The stock's GF Value™ is $28.56, compared to a current price of $31.60 — trading 10.6% above its estimated fair value. The current Days Payable is 52.40, which is 19% above median its 10-year median of 44.04 and 34.7% above the Healthcare Plans industry median of 38.89. Progyny's overall GF Score™ is 94/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Progyny (PGNY), the current Days Payable is 52.40 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Progyny (PGNY) Overvalued in 2026?
Based on GuruFocus' analysis, Progyny stock appears to be overvalued.
The current stock price of $31.60 is trading 10.6% above its estimated GF Value™ of $28.56.
GuruFocus considers Progyny to be Modestly Overvalued.
Key valuation signals for PGNY:
Days Payable: 52.40 (19% above median its 10-year median of 44.04)
GF Value™: $28.56 vs. price of $31.60 (10.6% above fair value)
Industry Position: 34.7% above the Healthcare Plans median (#5 of 13)
No single metric tells the full story. See the PGNY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Progyny Inc is a benefits management company specializing in fertility, family building, and women's health benefits solutions. Its clients include employers across various industries. The fertility benefits solution consists of treatment services (Smart Cycles), access to the Progyny network of high-quality fertility specialists that perform the Smart Cycle treatments, and active management of the selective network of high-quality provider clinics.
94GF Score
Get the complete analysis for PGNY
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PGNY has been successfully added to your 
